Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Rough calculation Start with 100 mCRC patients:

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 157631
(Total Views: 421)
Posted On: 10/02/2025 7:01:11 AM
Posted By: ohm20
Re: HouseofCards #157515
Quote:
Rough calculation

Start with 100 mCRC patients:
Heavily pretreated: ~65
MSS only: 85% → ~55
CCR5-positive: ~35% → ~19
ECOG 0–1 + organ function: ~45% → ~9
Exclusions: lose ~15% → ~8



There are approximately 1,400,000 colorectal cancer patients in the U.S. so even if you go by the 8% ChatGPT comes up with that's up to 112, 000 patients for our trial.

But what is the basis of ChatGPT's percentages. Let's take a look at just one aspect of that to see where the whole thing falls apart. One study showed 80% of CRC tumors to have some CCR5 expression. Most others show above 50%. mssCRC shows higher levels than mCRC. The level also increases as the tumor grows. So that 30% is out the window.

Looking at it from the treatment perspective CCR5 on the main tumor is of importance. But even CCR5 expression in the tumor microenvironment has a lot of import when it comes disease progression. A point I've made before is that even non-localized CCR5 has effect. CCR5 enhancing metastasis to other sites and protecting those metastatic lesions. The increase in killer macrophages that originate in the bone marrow. Even CCR5 increasing mesenchymal stem cells in the bome marrow that are tumor protectant.


(21)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us